Moma's a-Monogrid Products
Moma's lead programs are centered on the angiogenic properties of vascular growth factors secreted by monocytes in the unique environment of a-Monogrid©, and its capacity to generate new blood vessels in a target tissue.
Therapeutic angiogenesis involves multiple growth factors and cytokines. For this reason the delivery of specific vascular growth factors alone such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) to ischemic organs in patients failed to deliver a significant improvement. Recent studies have demonstrated that the efficacy of stem cell and progenitor cells depends critically on growth factors released by these cells. Moma's technology uses i-Monogrid to transform monocytes into efficient angiogenic engines, delivering vascular growth factors and other angiogenic cytokines directly to the ischemic tissue were they are most needed. Unlike single growth factors, the biodynamic delivery of multiple growth factors and cytokines produced by "expert" cells can deliver the signal complexity required for therapeutic angiogenesis.
MM-101 for Critical Limb Ischemia
MM-101 is designed for improving muscle perfusion in patients with Critical Limb Ischemia (CLI). Patients suffering from Peripheral Arterial Disease (PAD), a condition characterized by the narrowing and hardening of the arteries in the limbs, usually develop CLI. Approximately 10 million Americans suffer from PAD and, each year, 100,000 of these patients will have a limb amputation. Despite some success of limb salvage with leg bypass, CLI remains associated with a substantial rate of morbidity and mortality. MM-101 is administered by intramuscular injection in the affected area. MM-101's initial indication is targeted at the most severe patients, those who are not eligible for bypass or percutaneous revascularization.
MM-111 for Chronic Wound Healing
MM-111 Blood supply is paramount for wound healing. There are approximately 2 million Americans currently suffering from chronic wounds, a condition associated with a high rate of serious complications including amputation, systemic infection and death. MM-111 is administered subcutaneously and is designed to accelerate the healing of chronic wounds by enhancing local blood supply.
MM-121 for Ischemic Heart Disease
MM-121 is designed to improve myocardial perfusion in patients with Coronary Artery Disease (CAD), which affects 14 million people in the United States. A major consequence of CAD is myocardial infarction, or heart attack, which is the leading cause of death in the developed world. Advanced CAD typically requires revascularization for prevention of symptoms of angina and mortality.